TScan Therapeutics, Inc. Common Stock TCRX
$0.78
+0.88%
at last close
Analyst Consensus
- Consensus Rating
- Buy (3 Buy · 1 Hold · 0 Sell)
- Average Price Target
- $6.00
- Implied Upside
- +670.4%
- Price Target Range
- $5.00 – $7.00
- Analysts (12 mo)
- 4
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-08-12 | HC Wainwright & Co.Andres Y. Maldonado |
Reiterates | Buy | $7 |
| 2026-06-23 | WedbushDavid Nierengarten |
Reiterates | Outperform | $5 |
| 2026-06-23 | NeedhamGil Blum |
Reiterates | Buy | $6 |
| 2026-03-05 | WedbushDavid Nierengarten |
Maintains | Outperform | $4 → $5 |
| 2025-11-13 | HC Wainwright & Co.Andres Y. Maldonado |
Maintains | Buy | $10 → $7 |
| 2025-11-04 | BTIGJustin Zelin |
Downgrades | Buy → Neutral | — |
| 2025-11-04 | NeedhamGil Blum |
Maintains | Buy | $9 → $6 |
| 2025-05-07 | HC Wainwright & Co.Andres Maldonado |
Maintains | Buy | $15 → $10 |
| 2025-04-08 | NeedhamGil Blum |
Reiterates | Buy | $9 |
| 2025-03-14 | Morgan StanleyMaxwell Skor |
Assumes | Overweight | $10 |
| 2025-03-07 | BarclaysPeter Lawson |
Maintains | Overweight | $14 → $3 |
| 2025-03-06 | HC Wainwright & Co.Andrew Fein |
Reiterates | Buy | $15 |
| 2025-03-05 | NeedhamGil Blum |
Maintains | Buy | $11 → $9 |
| 2024-12-11 | HC Wainwright & Co.Andrew Fein |
Reiterates | Buy | $15 |
| 2024-12-11 | NeedhamGil Blum |
Reiterates | Buy | $11 |
| 2024-11-15 | HC Wainwright & Co.Andrew Fein |
Reiterates | Buy | $15 |
| 2024-11-12 | NeedhamGil Blum |
Reiterates | Buy | $11 |
| 2024-11-06 | NeedhamGil Blum |
Reiterates | Buy | $11 |
| 2024-08-13 | WedbushDavid Nierengarten |
Reiterates | Outperform | $10 |
| 2024-08-13 | HC Wainwright & Co.Andrew Fein |
Reiterates | Buy | $15 |
| 2024-08-12 | NeedhamGil Blum |
Reiterates | Buy | $11 |
| 2024-06-04 | HC Wainwright & Co.Andrew Fein |
Reiterates | Buy | $15 |
| 2024-05-16 | BTIGJustin Zelin |
Initiates coverage on | Buy | $12 |
| 2024-05-14 | HC Wainwright & Co.Andrew Fein |
Reiterates | Buy | $15 |
| 2024-05-13 | NeedhamGil Blum |
Reiterates | Buy | $11 |
| 2024-04-23 | WedbushDavid Nierengarten |
Reiterates | Outperform | $10 |
| 2024-03-07 | BarclaysPeter Lawson |
Maintains | Overweight | $7 → $9 |
| 2024-03-07 | HC Wainwright & Co.Andrew Fein |
Reiterates | Buy | $15 |
| 2024-02-01 | WedbushDavid Nierengarten |
Reiterates | Outperform | $9 |
| 2023-08-14 | HC Wainwright & Co.Andrew Fein |
Reiterates | Buy | $15 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $0.78
- Market Cap
- $52.39 million
- 52-Week Range
- $0.72 – $2.57
- Average Volume
- 658K shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.